NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer

被引:34
|
作者
Darvishi, Behrad [1 ]
Farahmand, Leila [1 ]
Eslami-S, Zahra [1 ]
Majidzadeh-A, Keivan [2 ]
机构
[1] ACECR, Breast Canc Res Ctr, Motamed Canc Inst, Recombinant Prot Dept, Tehran, Iran
[2] ACECR, Motamed Canc Inst, Breast Canc Res Ctr, Genet Dept, 146 South Gandhi Ave,Vanak Sq, Tehran 1517964311, Iran
关键词
Triple-negative breast cancer; nuclear factor-kappa B; receptor tyrosine kinase inhibitors; chemotherapy resistance; CELLULAR-TRANSFORMATION; AZD6244; ARRY-142886; ANTITUMOR-ACTIVITY; INFLAMMATION; PATHWAY; CELLS; STAT3; TUMOR; EXPRESSION; IL-6;
D O I
10.1177/1010428317706919
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although accounting for merely a minute portion of diagnosed breast cancers, disproportionate number of deaths and associated low survival rate of patients have made triple-negative breast cancer to be considered as the most lethal breast cancer subtype. More importantly, intrinsic or developed resistance to chemotherapeutic regimens and disappointing outcomes of trials associated with many newly developed agents are other obstacles in establishment of a durable response in these patients. Interestingly, these happen despite the outstanding preclinical outcomes observed by these agents, most importantly among them, targeted receptor tyrosine kinase inhibitors. Pursuing these disappointing outcomes, especially in the case of targeted receptor tyrosine kinase inhibitors, many researches have focused on identification of the hidden factors involved. Highly inflammatory, rich in reactive oxygen species, and hypoxic microenvironment of triple-negative breast cancer tumors and the involving mediators were the first suggestions for observed resistance and poor clinical outcomes of targeted receptor tyrosine kinase inhibitors. Interestingly, for all aberrantly expressed mediators observed in microenvironment, downstream pathways converge in a common node, nothing but the nuclear factor-kappa B, the insidious factor proposed to be the cause of many events opposing achievement of a desired outcome. In first section of current review, we describe the signaling pathways underlying activation of receptor tyrosine kinases and their convergence at the nuclear factor-kappa B node, and in next section, we demonstrate how unique hypoxic, inflammatory, rich in free-radical microenvironment of triple-negative breast cancer exacerbate pathways in which otherwise could become mostly suppressed by receptor tyrosine kinase inhibitors.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Resistance of triple-negative breast cancer cells to EGFR-targeted tyrosine kinase inhibitors is associated with Annexin A6-dependent metabolic reprogramming.
    Williams, Stephen D.
    Widatalla, Sarrah E.
    Sakwe, Amos M.
    CANCER RESEARCH, 2021, 81 (13)
  • [42] Activity Assay of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer Cells Using Peptide-Conjugated Magnetic Beads
    Ghosh, Gargi
    Yan, Xiaoliang
    Kron, Stephen J.
    Palecek, Sean P.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2013, 11 (01) : 44 - 51
  • [43] Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer
    Yao, Hang-Ping
    Suthe, Sreedhar Reddy
    Hudson, Rachel
    Wang, Ming-Hai
    DRUG DISCOVERY TODAY, 2020, 25 (07) : 1160 - 1173
  • [44] ROR activation by Nobiletin enhances antitumor efficacy via suppression of IκB/NF-κB signaling in triple-negative breast cancer
    Eunju Kim
    Yoon-Jin Kim
    Zhiwei Ji
    Jin Muk Kang
    Marvin Wirianto
    Keshav Raj Paudel
    Joshua A. Smith
    Kaori Ono
    Jin-Ah Kim
    Kristin Eckel-Mahan
    Xiaobo Zhou
    Hyun Kyoung Lee
    Ji Young Yoo
    Seung-Hee Yoo
    Zheng Chen
    Cell Death & Disease, 13
  • [45] ROR activation by Nobiletin enhances antitumor efficacy via suppression of IκB/NF-κB signaling in triple-negative breast cancer
    Kim, Eunju
    Kim, Yoon-Jin
    Ji, Zhiwei
    Kang, Jin Muk
    Wirianto, Marvin
    Paudel, Keshav Raj
    Smith, Joshua A.
    Ono, Kaori
    Kim, Jin-Ah
    Eckel-Mahan, Kristin
    Zhou, Xiaobo
    Lee, Hyun Kyoung
    Yoo, Ji Young
    Yoo, Seung-Hee
    Chen, Zheng
    CELL DEATH & DISEASE, 2022, 13 (04)
  • [46] Adjuvant chemotherapy in small node-negative triple-negative breast cancer
    Steenbruggen, Tessa G.
    van Werkhoven, Erik
    van Ramshorst, Mette S.
    van Ramshorst, Mette S.
    Dezentje, Vincent O.
    Kok, Marleen
    Linn, Sabine C.
    Siesling, Sabine
    Sonke, Gabe S.
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 66 - 74
  • [47] Novel synergy of radiosensitizer prodrug IPdR with Aurora kinase inhibitors in triple-negative breast cancer
    Rampurwala, Murtuza M.
    Choudhary, Alka
    Burkard, Mark E.
    CANCER RESEARCH, 2014, 74 (19)
  • [48] Identifying specific inhibitors of triple-negative breast cancer subtypes
    Robles, A. J.
    Cai, S.
    Du, L.
    Shaffer, C. V.
    Grkovic, T.
    Risinger, A. L.
    O'Keefe, B. R.
    Cichewicz, R. H.
    Mooberry, S. L.
    PLANTA MEDICA, 2016, 82
  • [49] The association between expression of prolactin receptor and lymph node involvement in triple-negative breast cancer
    Mohamadianamiri, Mahdiss
    Ebrahimi, Abdolali
    Farzaneh, Farah
    Aklami, Majid
    Momeni, Mina
    Hajighasem, Tannaz
    Shirazi, Hossein
    Zeinadini, Mohammadreza
    BREAST CANCER MANAGEMENT, 2022, 11 (04)
  • [50] NF-κB associated markers of prognosis in early and metastatic triple negative breast cancer
    Payton De La Cruz
    Julia McAdams
    Melanie Morales Aquino
    Aileen I. Fernandez
    Andrew Elliott
    Maryam Lustberg
    Christoph Schorl
    Jennifer R. Ribeiro
    Nicole E. James
    Breast Cancer Research, 26 (1)